Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes

Daishi Ichioka, Jun Miyazaki, Takamitsu Inoue, Susumu Kageyama, Mikio Sugimoto, Koji Mitsuzuka, Yoshiyuki Matsui, Yusuke Shiraishi, Hidefumi Kinoshita, Hironobu Wakeda, Takeshi Nomoto, Eiji Kikuchi, Hiroyuki Nishiyama

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: The aim of the study is to clarify the clinical effects of first-line chemotherapy regimens for advanced urothelial cancer on clinical responses and survival of patients grouped by renal function. Methods: In this multicenter retrospective cohort study, 345 urothelial cancer patients received systemic chemotherapy for metastatic or unresectable disease in 17 centers (2004-10). Results: Two hundred and forty-one patientswere treatedwithmethotrexate, vinblastine, doxorubicin and cisplatin/methotrexate, epirubicin and cisplatin (n = 136) or gemcitabine and cisplatin (n = 105) followed by carboplatin-based treatments, non-platinum treatments or other regimens. After 2008, gemcitabine and cisplatin was the most frequently used regimen in patients with an estimated glomerular filtration rate < 60 ml/min/1.73 m<sup>2</sup> and in those with estimated glomerular filtration rate ≥60 ml/ min/1.73 m<sup>2</sup>. The gemcitabine and cisplatin patients' complete response rate was 10.5% and their response ratewas 52.4%, whichwas highest among all regimens. Gemcitabine and cisplatin demonstrated a better 3-year overall survival when the estimated glomerular filtration rate was ≥60 ml/min/ 1.73 m<sup>2</sup> (31.4%), but it tended to be worse when the estimated glomerular filtration rate was < 60 ml/ min/1.73 m<sup>2</sup> (14.1%). In the latter cases, the dose reduction rate of gemcitabine and cisplatinwas high (43.9%). Among the patients with estimated glomerular filtration rate < 60 ml/min/1.73 m<sup>2</sup>, the 1-year overall survival of the patients treated with a reduced dose of gemcitabine and cisplatin was significantly lower than that of those treated with standard-dose gemcitabine and cisplatin (26.2 vs. 60.3%, respectively, P = 0.0108). Conclusions: Gemcitabine and cisplatin provided favorable responses and survival in patients with estimated glomerular filtration rate <60 ml/min/1.73 m<sup>2</sup> but unsatisfactory oncological outcomes in patients with estimated glomerular filtration rate < 60 ml/min/1.73 m<sup>2</sup>, especially when treated with a reduced dose. Alternative regimens might be optimal rather than reduced-dose gemcitabine and cisplatin in patients with estimated glomerular filtration rate < 60 ml/min/1.73 m<sup>2</sup>.

Original languageEnglish
Article numberhyv082
Pages (from-to)867-873
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume45
Issue number9
DOIs
Publication statusPublished - 2015 Sep 1

Fingerprint

gemcitabine
Cisplatin
Glomerular Filtration Rate
Kidney
Drug Therapy
Neoplasms
Survival
Epirubicin
Vinblastine
Carboplatin
Methotrexate
Doxorubicin

Keywords

  • Chemotherapy
  • Cisplatin
  • EGFR
  • Gemcitabine
  • Renal function
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes. / Ichioka, Daishi; Miyazaki, Jun; Inoue, Takamitsu; Kageyama, Susumu; Sugimoto, Mikio; Mitsuzuka, Koji; Matsui, Yoshiyuki; Shiraishi, Yusuke; Kinoshita, Hidefumi; Wakeda, Hironobu; Nomoto, Takeshi; Kikuchi, Eiji; Nishiyama, Hiroyuki.

In: Japanese Journal of Clinical Oncology, Vol. 45, No. 9, hyv082, 01.09.2015, p. 867-873.

Research output: Contribution to journalArticle

Ichioka, D, Miyazaki, J, Inoue, T, Kageyama, S, Sugimoto, M, Mitsuzuka, K, Matsui, Y, Shiraishi, Y, Kinoshita, H, Wakeda, H, Nomoto, T, Kikuchi, E & Nishiyama, H 2015, 'Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes', Japanese Journal of Clinical Oncology, vol. 45, no. 9, hyv082, pp. 867-873. https://doi.org/10.1093/jjco/hyv082
Ichioka, Daishi ; Miyazaki, Jun ; Inoue, Takamitsu ; Kageyama, Susumu ; Sugimoto, Mikio ; Mitsuzuka, Koji ; Matsui, Yoshiyuki ; Shiraishi, Yusuke ; Kinoshita, Hidefumi ; Wakeda, Hironobu ; Nomoto, Takeshi ; Kikuchi, Eiji ; Nishiyama, Hiroyuki. / Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes. In: Japanese Journal of Clinical Oncology. 2015 ; Vol. 45, No. 9. pp. 867-873.
@article{4b388162b531426aa190cb37894184f5,
title = "Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes",
abstract = "Objective: The aim of the study is to clarify the clinical effects of first-line chemotherapy regimens for advanced urothelial cancer on clinical responses and survival of patients grouped by renal function. Methods: In this multicenter retrospective cohort study, 345 urothelial cancer patients received systemic chemotherapy for metastatic or unresectable disease in 17 centers (2004-10). Results: Two hundred and forty-one patientswere treatedwithmethotrexate, vinblastine, doxorubicin and cisplatin/methotrexate, epirubicin and cisplatin (n = 136) or gemcitabine and cisplatin (n = 105) followed by carboplatin-based treatments, non-platinum treatments or other regimens. After 2008, gemcitabine and cisplatin was the most frequently used regimen in patients with an estimated glomerular filtration rate < 60 ml/min/1.73 m2 and in those with estimated glomerular filtration rate ≥60 ml/ min/1.73 m2. The gemcitabine and cisplatin patients' complete response rate was 10.5{\%} and their response ratewas 52.4{\%}, whichwas highest among all regimens. Gemcitabine and cisplatin demonstrated a better 3-year overall survival when the estimated glomerular filtration rate was ≥60 ml/min/ 1.73 m2 (31.4{\%}), but it tended to be worse when the estimated glomerular filtration rate was < 60 ml/ min/1.73 m2 (14.1{\%}). In the latter cases, the dose reduction rate of gemcitabine and cisplatinwas high (43.9{\%}). Among the patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2, the 1-year overall survival of the patients treated with a reduced dose of gemcitabine and cisplatin was significantly lower than that of those treated with standard-dose gemcitabine and cisplatin (26.2 vs. 60.3{\%}, respectively, P = 0.0108). Conclusions: Gemcitabine and cisplatin provided favorable responses and survival in patients with estimated glomerular filtration rate <60 ml/min/1.73 m2 but unsatisfactory oncological outcomes in patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2, especially when treated with a reduced dose. Alternative regimens might be optimal rather than reduced-dose gemcitabine and cisplatin in patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2.",
keywords = "Chemotherapy, Cisplatin, EGFR, Gemcitabine, Renal function, Urothelial cancer",
author = "Daishi Ichioka and Jun Miyazaki and Takamitsu Inoue and Susumu Kageyama and Mikio Sugimoto and Koji Mitsuzuka and Yoshiyuki Matsui and Yusuke Shiraishi and Hidefumi Kinoshita and Hironobu Wakeda and Takeshi Nomoto and Eiji Kikuchi and Hiroyuki Nishiyama",
year = "2015",
month = "9",
day = "1",
doi = "10.1093/jjco/hyv082",
language = "English",
volume = "45",
pages = "867--873",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes

AU - Ichioka, Daishi

AU - Miyazaki, Jun

AU - Inoue, Takamitsu

AU - Kageyama, Susumu

AU - Sugimoto, Mikio

AU - Mitsuzuka, Koji

AU - Matsui, Yoshiyuki

AU - Shiraishi, Yusuke

AU - Kinoshita, Hidefumi

AU - Wakeda, Hironobu

AU - Nomoto, Takeshi

AU - Kikuchi, Eiji

AU - Nishiyama, Hiroyuki

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objective: The aim of the study is to clarify the clinical effects of first-line chemotherapy regimens for advanced urothelial cancer on clinical responses and survival of patients grouped by renal function. Methods: In this multicenter retrospective cohort study, 345 urothelial cancer patients received systemic chemotherapy for metastatic or unresectable disease in 17 centers (2004-10). Results: Two hundred and forty-one patientswere treatedwithmethotrexate, vinblastine, doxorubicin and cisplatin/methotrexate, epirubicin and cisplatin (n = 136) or gemcitabine and cisplatin (n = 105) followed by carboplatin-based treatments, non-platinum treatments or other regimens. After 2008, gemcitabine and cisplatin was the most frequently used regimen in patients with an estimated glomerular filtration rate < 60 ml/min/1.73 m2 and in those with estimated glomerular filtration rate ≥60 ml/ min/1.73 m2. The gemcitabine and cisplatin patients' complete response rate was 10.5% and their response ratewas 52.4%, whichwas highest among all regimens. Gemcitabine and cisplatin demonstrated a better 3-year overall survival when the estimated glomerular filtration rate was ≥60 ml/min/ 1.73 m2 (31.4%), but it tended to be worse when the estimated glomerular filtration rate was < 60 ml/ min/1.73 m2 (14.1%). In the latter cases, the dose reduction rate of gemcitabine and cisplatinwas high (43.9%). Among the patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2, the 1-year overall survival of the patients treated with a reduced dose of gemcitabine and cisplatin was significantly lower than that of those treated with standard-dose gemcitabine and cisplatin (26.2 vs. 60.3%, respectively, P = 0.0108). Conclusions: Gemcitabine and cisplatin provided favorable responses and survival in patients with estimated glomerular filtration rate <60 ml/min/1.73 m2 but unsatisfactory oncological outcomes in patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2, especially when treated with a reduced dose. Alternative regimens might be optimal rather than reduced-dose gemcitabine and cisplatin in patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2.

AB - Objective: The aim of the study is to clarify the clinical effects of first-line chemotherapy regimens for advanced urothelial cancer on clinical responses and survival of patients grouped by renal function. Methods: In this multicenter retrospective cohort study, 345 urothelial cancer patients received systemic chemotherapy for metastatic or unresectable disease in 17 centers (2004-10). Results: Two hundred and forty-one patientswere treatedwithmethotrexate, vinblastine, doxorubicin and cisplatin/methotrexate, epirubicin and cisplatin (n = 136) or gemcitabine and cisplatin (n = 105) followed by carboplatin-based treatments, non-platinum treatments or other regimens. After 2008, gemcitabine and cisplatin was the most frequently used regimen in patients with an estimated glomerular filtration rate < 60 ml/min/1.73 m2 and in those with estimated glomerular filtration rate ≥60 ml/ min/1.73 m2. The gemcitabine and cisplatin patients' complete response rate was 10.5% and their response ratewas 52.4%, whichwas highest among all regimens. Gemcitabine and cisplatin demonstrated a better 3-year overall survival when the estimated glomerular filtration rate was ≥60 ml/min/ 1.73 m2 (31.4%), but it tended to be worse when the estimated glomerular filtration rate was < 60 ml/ min/1.73 m2 (14.1%). In the latter cases, the dose reduction rate of gemcitabine and cisplatinwas high (43.9%). Among the patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2, the 1-year overall survival of the patients treated with a reduced dose of gemcitabine and cisplatin was significantly lower than that of those treated with standard-dose gemcitabine and cisplatin (26.2 vs. 60.3%, respectively, P = 0.0108). Conclusions: Gemcitabine and cisplatin provided favorable responses and survival in patients with estimated glomerular filtration rate <60 ml/min/1.73 m2 but unsatisfactory oncological outcomes in patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2, especially when treated with a reduced dose. Alternative regimens might be optimal rather than reduced-dose gemcitabine and cisplatin in patients with estimated glomerular filtration rate < 60 ml/min/1.73 m2.

KW - Chemotherapy

KW - Cisplatin

KW - EGFR

KW - Gemcitabine

KW - Renal function

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=84942328455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942328455&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyv082

DO - 10.1093/jjco/hyv082

M3 - Article

C2 - 26056328

AN - SCOPUS:84942328455

VL - 45

SP - 867

EP - 873

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

M1 - hyv082

ER -